Sivifene

Drug Profile

Sivifene

Alternative Names: A-007

Latest Information Update: 20 Jul 2015

Price : $50

At a glance

  • Originator Barbara Ann Karmanos Cancer Institute; Dekk-Tec
  • Developer Kirax Corporation
  • Class Antineoplastics; Hydrazones; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anal intraepithelial neoplasia; Breast cancer; Cervical cancer; Cervical intraepithelial neoplasia; Kaposi's sarcoma; Lymphoma; Malignant melanoma

Most Recent Events

  • 03 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events section
  • 18 Jan 2007 Tigris Pharmaceuticals completes enrolment in the phase I/II trial for Anal intraepithelial neoplasia in USA
  • 18 Jan 2007 Tigris Pharmaceuticals completes enrolment in two registrational clinical trials for Cervical intraepithelial neoplasia in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top